902 Development Partners International (DPI), British International Investment (BII), the UK government’s Development Finance Institution, and the European Bank for Reconstruction and Development (EBRD), have sold 100% of the shares in KELIX bio, an emerging markets biopharmaceuticals platform, to Mubadala Investment Company (Mubadala), the Abu Dhabi investor with over $276bn in assets under management.